Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems

Not Applicable

Completed

• Conditions: Electronic Cigarette Use
• Interventions: Other: E-cigarette Flavor; Other: Tobacco Free Nicotine Pouch

• Registration Number: NCT05423340
• Lead Sponsor: Roswell Park Cancer Institute

Brief Summary

This is a randomized, parallel-group open-label trial to evaluate respiratory symptoms in ENDS users switching from banned flavors to a non-banned flavor (tobacco) or 'tobacco free' nicotine pouches.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-06-03
• Study Start: 2022-06-12
• Study First Submitted QC: 2022-06-13
• Study First Posted: 2022-06-21
• Primary Completion: 2024-10-03
• Study Completion: 2024-10-03
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-24
• Last Update Posted: 2025-01-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 163

Inclusion Criteria

• ENDS users as determined by: (a) using banned flavored ENDS with nicotine such as fruit, candy, dessert flavors, and/or any product that indicates such flavors (b) using ENDS daily, regularly for the past 6 months (self-reported).
• No smoking tobacco or using smokeless tobacco for the past 6 months.
• Subjects should be free of acute respiratory illness within the proceeding 30 days prior to recruitment (self-reported).
• Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
• After receiving information regarding the NYS flavor ban individuals must not want to quit vaping or stop using their flavored product for the next 90 days.

Exclusion Criteria

• Individuals with health conditions and therapies that may affect immune responses and levels of inflammatory markers, including allergic rhinitis, aspirin/NSAID therapy, asthma, immunodeficiency (HIV or other), Guillain-Barre Syndrome, COPD, or fever/respiratory illness within 30 days prior to entry into study (self-reported).
• Pregnant or nursing female participants (self-reported on telephone screener, pregnancy test on Visit#1)
• Unable to communicate in English.
• Unable or unwilling to follow protocol requirements.
• Self-report having active, untreated medical/psychiatric conditions.
• History of serious side effects from nicotine or from any nicotine replacement therapies.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Vulnerable populations, such as cognitively impaired adults, individuals who are not yet adults, pregnant women, and prisoners.
• Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug.
• After receiving information about the NYS flavor ban, participants who report that they are thinking about quitting or stop using their flavor within the next 90 days.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Use Own Brand of Flavored Product	E-cigarette Flavor	Participants will use their current flavor of e cigarettes for 90 days
Use Provided Tobacco Flavor	E-cigarette Flavor	Participants will use a new assigned flavor for 90 days
Vaping Abstinence - use "Tobacco Free" Nicotine Pouches	Tobacco Free Nicotine Pouch	Participants will be asked to stop vaping for 90 days and instead only use the provided 'tobacco free' nicotine pouches.

Primary Outcome Measures

Name	Time	Method
Respiratory tract inflammation activity	Up to 90 days	Exhaled Nitric Oxide (FeNo)l be measured in participants' breath using a FDA cleared monitor NIOX VERO (Aerocrine) according to ATS guidelines. FeNO has been used to monitor airway inflammation to account for persistent and/or high allergen exposure as a factor associated with higher levels of FeNO
Risk biomarkers of inflammation and oxidative stress as measured by ELISA	Up to 90 days	Oxidative stress and inflammation in plasma using ELISA . A quantitative measure of expression (units:pg/mg) will be produced.

Secondary Outcome Measures

Name	Time	Method
Amount of recent flavored product use	UP to 90 days	Assessed using the PhenX Toolkit which tracks tobacco use and asks subjects to retrospectively estimate product use,
Frequency of flavored product use	Up to 90 days	Questions from Wave 1 Adult PATH Survey to measure use and regularity of use flavored products
Flavor Preference questionnaire	Up to 90 days	Personal flavor questionnaire to determine flavor preference when using ENDS.

Trial Locations

Locations (1)

Roswell Park Comprehensive Cancer Center; 🇺🇸 Buffalo, New York, United States